Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Manufacturers	Review Status	Status Date	View
JXSS1800002	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-02-11	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2018-07-26	view
JXSL1800009	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-03-29	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	Certificate Issued	2018-07-17	view
JXSL1800016	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-07-25	默沙东研发(中国)有限公司	MSD R&D (China) Co Ltd	Certificate Issued	2018-09-25	view
JXSL1800021	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-08-22	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	Certificate Issued	2018-10-22	view
JXSL1800030	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-09-12	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	Certificate Issued	2018-10-29	view
JXSS1800018	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-09-18	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2019-04-02	view
JYSB1800199	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2018-09-25	Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2018-11-27	view
JXSS1800025	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-10-22	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2019-11-28	view
JYSB1800220	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2018-10-22	Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2019-06-13	view
JXSS1800029	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-11-12	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Merck Sharp & Dohme Corp	Certificate Issued	2019-10-15	view
JXSL1800048	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-11-12		Merck Sharp & Dohme Corp	In Review	2018-11-09	view
JYSB1800259	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2018-11-28			In Review	2018-11-27	view
JXSL1800055	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2018-11-28		Merck Sharp & Dohme Corp	In Review	2018-11-27	view
JYSB1800281	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2018-12-10	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp	In Review	2018-12-08	view
JYSB1800307	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Supplementary Application	2019-01-02			In Review	2018-12-30	view
JXSL1900013	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2019-02-18	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2019-02-15	view
JXSL1900012	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2019-02-18	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2019-02-15	view
JXSL1900016	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2019-02-18	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2019-02-15	view
JXSL1900017	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2019-02-20	默沙东研发（中国）有限公司	MSD R&D (China) Co Ltd	In Review	2019-02-19	view
JXSL1900039	帕博利珠单抗注射液	pembrolizumab	Injection	Biological Products	Import Drug Application	2019-03-29		Merck Sharp & Dohme Corp	In Review	2019-03-28	view